<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7906158</journal-id>
<journal-id journal-id-type="pubmed-jr-id">7844</journal-id>
<journal-id journal-id-type="nlm-ta">Trends Pharmacol Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Trends Pharmacol. Sci.</journal-id>
<journal-title-group>
<journal-title>Trends in pharmacological sciences</journal-title>
</journal-title-group>
<issn pub-type="ppub">0165-6147</issn>
<issn pub-type="epub">1873-3735</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30824180</article-id>
<article-id pub-id-type="pmc">6445545</article-id>
<article-id pub-id-type="doi">10.1016/j.tips.2019.02.006</article-id>
<article-id pub-id-type="manuscript">NIHMS1522735</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neuropharmacological Insight from Allosteric Modulation of mGlu Receptors</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Stansley</surname>
<given-names>Branden J.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Conn</surname>
<given-names>P. Jeffrey</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA</aff>
<aff id="A2"><label>2</label>Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232, USA</aff>
<author-notes>
<corresp id="CR1"><label>*</label><italic>Correspondence:</italic><email>jeffrey.conn@vanderbilt.edu</email>, Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, 1205 Light Hall, Nashville, TN 37232-0697, (615) 875-9770</corresp>
<fn fn-type="COI-statement" id="FN2">
<p id="P33">Conflict of interest statement</p>
<p id="P34">P.J.C. receives research support from Lundbeck Pharmaceuticals and are inventors on multiple patents for allosteric modulators for several classes’ metabotropic glutamate receptors.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>12</day>
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>26</day>
<month>2</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>4</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>4</month>
<year>2020</year>
</pub-date>
<volume>40</volume>
<issue>4</issue>
<fpage>240</fpage>
<lpage>252</lpage>
<!--elocation-id from pubmed: 10.1016/j.tips.2019.02.006-->
<abstract id="ABS1">
<p id="P1">The metabotropic glutamate (mGlu) receptors are a family of G protein-coupled receptors that regulate cell physiology throughout the nervous system. The potential of mGlu receptors as therapeutic targets has been bolstered by current research that has provided insight into the diverse modes of mGlu activation and signaling. Particularly, the allosteric modulation of mGlu receptors represents a major area of focus in studies of basic pharmacology as well as drug development, largely due to the high subtype specificity achievable by targeting allosteric sites on mGlu receptors. These provide sophisticated regulation of neuronal excitability and synaptic transmission to influence behavioral output. Here, we review how these allosteric mechanisms have been leveraged preclinically to demonstrate the therapeutic potential of allosteric modulators for neurological and neuropsychiatric disorders such as autism, cognitive impairment, Parkinson’s disease, stress, and schizophrenia.</p>
</abstract>
<kwd-group>
<kwd>mGlu</kwd>
<kwd>allosteric modulators</kwd>
<kwd>CNS</kwd>
<kwd>stimulus bias</kwd>
<kwd>drug discovery</kwd>
<kwd>neuropsychiatric disorders</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>